Screening period up to liver transplantation: -Written informed consent obtained before any assessment.
Male or female subjects between 18 to 70 years of age.
Recipients of a primary liver transplant from a deceased donor.
Up to date vaccination as per local immunization schedules.
Recipients tested negative for HIV.
MELD score ≤30.
Recipients with no active HCV and HBV replication (no detectable RNA/DNA by PCR).
Allograft is functioning at an acceptable level by the time of randomization as defined by AST, ALT, Total Bilirubin, and Alkaline Phosphatase levels ≤ 5 times ULN.
Renal function (eGFR, MDRD-4 formula) ≥ 30 mL/min/1.73 m2 based on most recent post-transplant value prior to randomization.
Screening period up to liver transplantation:
Recipients of a liver from a donor after cardiac death (DCD), from a living donor, or of a split liver.
A negative Epstein Barr virus (EBV) test.
Recipients receiving an ABO incompatible allograft.
History of malignancy of any organ system treated or untreated, within the past 5 years.
Hepatocellular carcinoma that does not fulfill Milan criteria.
Recipients transplanted for acute liver failure.
Any use of antibody induction therapy, or use of any immunosuppressive medications
Patients who have received a live vaccine within four weeks prior to transplantation.
Recipients with donors HIV positive, HBsAg positive, HCV positive.
Recipients with donors with hepatic steatosis > 30%.
Any post-transplant history of thrombosis, occlusion or stent placement in any hepatic arteries, hepatic veins, portal vein or inferior vena cava at any time during the run-in period prior to randomization.
Recipients with platelet count < 50,000/mm3, an absolute neutrophil count of < 1,000/mm³ or white blood cell count of < 2,000/mm³.
Recipients with clinically significant systemic infection requiring use of intravenous (IV) antibiotics.
Evidence of active tuberculosis (TB) infection.
Any episode of acute rejection or suspected rejection prior to randomization.